Thallous Chloride Tl 201

Thallous Chloride Tl 201
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Thallous Chloride Tl 201 is a Thallous Chloride Tl 201 that is FDA approved for the diagnosis of myocardial infarction, ischemic heart disease, parathyroid hyperactivity. Common adverse reactions include anaphylactoid reactions,itching, nausea/vomiting, mild diarrhea, tremor, shortness of breath, conjunctivitis.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Thallous Chloride TI 201 Injection may be useful in myocardial perfusion imaging using either planar or SPECT (Single Photon Computed Tomography) techniques for the diagnosis and localization of myocardial infarction. It may also have prognostic value regarding survival, when used in the clinically stable patient following the onset of symptoms of an acute myocardial infarction, to assess the site and size of the perfusion defect.

Thallous Chloride TI 201 Injection may also be useful in conjunction with exercise stress testing as an adjunct in the diagnosis of ischemic heart disease (atherosclerotic coronary artery disease).

It is usually not possible to differentiate recent from old myocardial infarction, or to differentiate between recent myocardial infarction and ischemia.

Thallous Chloride TI 201 Injection is indicated also for the localization of sites of parathyroid hyperactivity in patients with elevated serum calcium and parathyroid hormone levels. It may also be useful in pre-operative screening to localize extrathyroidal and mediastinal sites of parathyroid hyperactivity and for postsurgical reexamination. Thallous Chloride Tl 201 Injection has not been adequately demonstrated to be effective for the localization of normal parathyroid glands.

Dosage

The recommended adult dose of intravenous Thallous Chloride Tl 201 Injection for planar myocardial imaging is 37 to 74 MBq (1-2 mCi). The recommended intravenous doses for SPECT myocardial imaging are 74 to 111 MBq (2-3 mCi). The efficacy of a 1.0 mCi dose SPECT imaging has not been well established.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

For patients undergoing resting thallium studies, imaging is optimally begun within 10-20 minutes after injection. Several investigators have reported improved myocardial-to-background ratios when patients are injected in the fasting state, in an upright posture, or after briefly ambulating. The upright position reduces the hepatic and gastric Thallium TI 201 concentration.

Best results with thallium imaging performed in conjunction with exercise stress testing appear to be obtained if the thallium is administered when the patient reaches maximum stress and when the stress is continued for 30 seconds to one minute after injection. Imaging should begin within ten minutes post-injection since target-to-background ratio is optimum by that time. Several investigators have reported significant decreases in the target-to-background ratios of lesions attributable to transient ischemia by two hours after the completion of stress Imaging.

For the localization of parathyroid hyperactivity, Thallous Chloride Tl 201 Injection may be administered before, with or after a minimal dose of a thyroid imaging agent such as sodium pertechnetate Tc99m or sodium iodide I 123 to enable thyroid subtraction imaging.

Based on data gathered in humans by Krahwinkel et al. (J Nucl Med 29(9):1582-1586, 1988) and data gathered in humans by Gupta et al. (Int J Nucl Med & Biol 8:211-213, 1981).

Bladder voiding interval 4.8hr. Contaminants assumed: TI-200 (0.3%), TI-202 (0.84%), Pb-203 (0.2%). Includes dose from TI-201 Auger electrons. Estimate calculated using phantom of Cristy & Eckerman (Report ORNL/TM-8381/V1 & V7). Radiation Internal Dose Information Center.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Thallous Chloride Tl 201 in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Thallous Chloride Tl 201 in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

safety and effectiveness of thallous chloride TI 201 have not been established in pediatric patients

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Thallous Chloride Tl 201 in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Thallous Chloride Tl 201 in pediatric patients.

Contraindications

• Condition1

Warnings

• Description

Precautions

• Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Thallous Chloride Tl 201 in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Thallous Chloride Tl 201 in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Drug Interactions

• Drug

• Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

• Pregnancy Category

Pregnancy Category (AUS):

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Thallous Chloride Tl 201 in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Thallous Chloride Tl 201 during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Thallous Chloride Tl 201 with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Thallous Chloride Tl 201 with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Thallous Chloride Tl 201 with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Thallous Chloride Tl 201 with respect to specific gender populations.

Race

There is no FDA guidance on the use of Thallous Chloride Tl 201 with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Thallous Chloride Tl 201 in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Thallous Chloride Tl 201 in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Thallous Chloride Tl 201 in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Thallous Chloride Tl 201 in patients who are immunocompromised.

Administration and Monitoring

Administration

• Oral

• Intravenous

Monitoring

There is limited information regarding Monitoring of Thallous Chloride Tl 201 in the drug label.

• Description

IV Compatibility

There is limited information regarding IV Compatibility of Thallous Chloride Tl 201 in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

• Description

Management

• Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Thallous Chloride Tl 201 in the drug label.

Pharmacology

There is limited information regarding Thallous Chloride Tl 201 Pharmacology in the drug label.

Mechanism of Action

Structure

File:Thallous Chloride Tl 20101.png

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Thallous Chloride Tl 201 in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Thallous Chloride Tl 201 in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Thallous Chloride Tl 201 in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Thallous Chloride Tl 201 in the drug label.

How Supplied

Storage

There is limited information regarding Thallous Chloride Tl 201 Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Thallous Chloride Tl 201 |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Thallous Chloride Tl 201 |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Thallous Chloride Tl 201 in the drug label.

Precautions with Alcohol

• Alcohol-Thallous Chloride Tl 201 interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

• ®

Look-Alike Drug Names

• A® — B®

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Page Name=Thallous Chloride Tl 201
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Thallous Chloride Tl 201
 |Label Name=Thallous Chloride Tl 20111.png

}}

{{#subobject:

 |Label Page=Thallous Chloride Tl 201
 |Label Name=Thallous Chloride Tl 20111.png

}}